Drugmaker Wockhardt expects to pay off external debt of ₹110 crore and invest in clinical trials of innovative antibiotic pipeline including its lead novel drug WCK5222 undergoing global phase-3 study, following capital raise of ₹480 crore through qualified institutional placement (QIP).'We are facing liquidity challenges; the fund raise will help us to focus on business,' said Dr Habil Khorakiwala, chairperson of Wockhardt, to ET.Khorakiwala said he expects Wockhardt revenues to grow 20% and earnings before interest, tax, depreciation and ammortisation (EBITDA) by 3%.Following the repayment of external debt, Wockhardt will still be left with debt of ₹1,000 crore it owes to the promoter Khorakiwala family.Wockhardt is investing $25 million on a late-stage global clinical trial of its lead antibiotic drug candidate, WCK5222, across 70 centres in 11 countries including the US, Europe, India, China and Latin America.'We have completed two-thirds of the trial, and expect US approval in early 2025,' Khorakiwala said.Khorakiwala added that they are exploring out-licensing deals to commercialise the drug in North America, Europe and Japan while the company will do it on its own in India and other emerging markets.WCK5222, called Zaynich, belongs to a new class of antibiotic known as 'ß-lactam enhance'.

制药商沃克哈特（Wockhardt）预计将偿还₹1.1亿欧元，并投资于创新抗生素管道的临床试验，包括其领先的新药WCK5222，正在进行全球3期研究₹通过合格机构安置（QIP）获得4.8亿欧元。”我们面临流动性挑战；沃克哈特董事长哈比勒·霍拉基瓦拉（HabilKhorakiwala）博士（to ET）说，此次资金筹集将有助于我们专注于商业。霍拉基瓦拉（Khorakiwala）预计沃克哈特的收入将增长20%，息税折旧及摊销前利润（EBITDA）将增长3%。偿还外债后，沃克哈特仍将背负₹这要归功于发起人Khorakiwala家族。沃克哈特（Wockhardt）正在投资2500万美元，在美国、欧洲、印度、中国和拉丁美洲等11个国家的70个中心对其主要抗生素候选药物WCK5222进行后期全球临床试验霍拉基瓦拉说，我们已经完成了三分之二的试验，预计美国将在2025年初获得批准。Khorakiwala补充说，他们正在探索许可协议，以便在北美、欧洲和日本将该药物商业化，而该公司将在印度和其他新兴市场自行开展这项工作。WCK5222，称为Zaynich，属于一类新的抗生素，称为“β-内酰胺增强剂”。

The drug is used to treat complicated urinary tract infections, including acute pyelonephritis - a bacterial infection affecting kidneys. For its other novel drug WCK4873, used to treat community-acquired bacterial pneumonia, Wockhardt is planning to complete India trials and launch it before the end of this year.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

该药物用于治疗复杂的尿路感染，包括急性肾盂肾炎-一种影响肾脏的细菌感染。对于用于治疗社区获得性细菌性肺炎的另一种新药WCK4873，沃克哈特计划在印度完成试验，并在今年年底前推出。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。